CGEN — Compugen Ltd.

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, Compugen reported approximately $145.6 million in cash, cash equivalents, and marketable securities, bolstered by a $65 million upfront payment from AstraZeneca.
• Revenue: Q4 2025 revenues were approximately $67.3 million, with total revenues for the year reaching $72.8 million, significantly up from $1.5 million in Q4 2024 and $27.9 million for the full year 2024.
• Net Profit: The company reported a net profit of $56.8 million (or $0.60 per share) for Q4 2025, compared to a net loss of $6.1 million in Q4 2024. For the full year, net profit was $35.3 million (or $0.38 per share), a turnaround from a net loss of $14.2 million in 2024.

2. Strategic Updates and Business Highlights

• Cash Runway Extension: The company extended its cash runway into 2029 through a non-dilutive transaction with AstraZeneca related to rilvegostomig.
• Clinical Advancements: Compugen initiated new clinical trials for its anti-PVRIG COM701 and anti–IL-18 binding protein GS-0321, expanding its clinical footprint in the U.S., Israel, and France.
• Leadership Transition: Dr. Eran Ophir became CEO in September 2025, with Anat Cohen-Dayag transitioning to Executive Chair, aiming to enhance operational focus and strategic continuity.

3. Forward Guidance and Outlook

• 2026 Strategic Priorities: The company plans to focus on the MAIA ovarian adaptive trial, with an interim analysis expected in Q1 2027. They aim to explore broader clinical development plans for COM701 and continue advancing GS-0321.
• Milestone Payments: Compugen is eligible for up to $195 million in future milestones from AstraZeneca, with the next milestone tied to the BLA acceptance.

4. Bad News, Challenges, or Points of Concern

• Trial Delays: The timeline for the interim analysis of the MAIA trial has shifted to 2027, attributed to slower site openings and event accumulation, which may raise concerns about the pace of clinical development.
• Market Competition: The company faces competitive pressures in the immuno-oncology space, particularly regarding the development of TIGIT-targeting therapies, where differentiation in product format and clinical strategy will be critical.

5. Notable Q&A Insights

• COM701 Update Expectations: During the Q&A, management indicated that the upcoming Q1 2027 update for COM701 will depend on data maturation, with potential paths for registration discussed.
• Rilvegostomig Milestones: The next significant milestone for rilvegostomig is the BLA acceptance, which will trigger a $25 million payment.
• Gilead Collaboration: Compugen is in alignment with Gilead regarding the reporting of data for GS-0321, with expectations that updates will be presented at scientific conferences, although specific timelines remain unconfirmed.

Overall, Compugen Ltd. demonstrated strong financial performance in 2025, with strategic advancements in clinical programs and a solid cash position, while also facing challenges related to trial timelines and competitive pressures.